AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

To protect commercial confidentiality the following appraisals will be held in private

5. Appraisal 1: Full Submission (WPAS)
   Pegvisomant (Somavert®) for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated

6. Appraisal 2: Full Submission (WPAS)
   Levodopa-carbidopa intestinal gel (Duodopa®) for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results

The meeting will now open to the public

7. Chairman's report (verbal update)

8. Appraisal 3: Full Submission
   Stiripentol (Diacomit®) in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate

Date of next meeting – Wednesday, 6th December 2017 in Cardiff